Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119160) titled 'The efficacy and safety of adjuvant TACE in radical surgery for hepatocellular carcinoma with high-risk recurrence factors: A phase III randomized controlled clinical study' on Feb. 24.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Guangxi Medical University Cancer Hospital
Condition:
Hepatocellular carcinoma
Intervention:
Adjuvant TACE:Adjuvant TACE
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollment: 2026-02-24
Target Sample Size: Adjuvant TACE:151;Active Surveillance:152;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/...